Published in Biotech Business Week, October 11th, 2004
Wet AMD, the most aggressive form of AMD and visual impairment, is particularly lucrative with therapeutic developments such as angiogenesis inhibitors, gene vaccines, and vascular endothelial growth factor (VEGF).
New analysis from Frost & Sullivan, Strategic Analysis of the Age-Related Macular Degeneration, Diabetic Retinopathy, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.